Global Information
회사소개 | 문의 | 비교리스트

의료용 3D 프린팅 : 테마별 조사

3D Printing in Healthcare - Thematic Research

리서치사 GlobalData
발행일 2020년 05월 상품 코드 939341
페이지 정보 영문 74 Pages
가격
US $ 1,950 ₩ 2,235,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,900 ₩ 4,471,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,850 ₩ 6,707,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


의료용 3D 프린팅 : 테마별 조사 3D Printing in Healthcare - Thematic Research
발행일 : 2020년 05월 페이지 정보 : 영문 74 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

3D 프린팅 기술은 산업, 전기, 항공우주, 자동차, 소비자, 의료 등 다양한 분야에서 사용되고 있습니다. 의료 부문에서는 재생의료 및 조직공학에 이용하는 인간의 생세포 및 조직, 정밀 의약품·맞춤형 의약품, 의지, 정형외과 및 치과용 임플란트, 외과 기구, 의학 교육 모델 등 의료기기의 제조 등에 이용되고 있습니다. 인간의 조직 및 세포의 3D 바이오프린팅은 재생의료, 기능 장기 치환, Drug Discovery 등 의료에서의 많은 중요한 미충족 요구를 충족할 가능성이 있습니다. 고령화가 진행되며 기증자 장기의 수요는 높아지고 있습니다. 바이오 프린트에 의한 환자 유래 줄기세포를 이용한 재생의료는 특정 질환의 맞춤형 의료를 가능하게 합니다. Drug Discovery에서는 바이오 프린트 인체조직을 이용함으로써 동물 조직에 비해 보다 신속하고 효율적인 프로세스가 가능해지며, 더 나은 결과를 얻을 수 있습니다. 또한 의약품 및 화장품의 개발에서 동물 실험을 없앨 수 있습니다. 이번 신종 코로나바이러스 감염증(COVID-19)은 세계의 의료 시스템에 큰 부담을 주고 있으며, 중요 의료기기 및 소모품에 대한 수요가 높아지고 있습니다. 대형 제조업체로부터 스타트업 기업 및 개인에 이르기까지 3D 프린팅 업계는 COVID-19의 위기에 대응하고 감염 확대 방지에 주력하는 병원을 위해 인공호흡기 및 개인보호장비(PPE) 등 중요 의료기기의 생산 지원을 약속하고 있습니다.

세계의 의료용 3D 프린팅 시장을 조사했으며, 특히 3D 바이오프린팅과 3D 프린트 의약품 제조에 초점을 맞추고 산업 및 기술의 개요, 법규제 환경, 시장 규모·성장 예측, 비용 분석, 주요 거래, 사례 연구, 밸류체인, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제2장 참여 기업

제3장 산업 동향

  • 헬스케어 부문의 동향
  • 기술 동향
  • 거시경제의 동향
  • 규제 동향
  • 3D 프린팅 : 헬스케어 산업에 대한 영향

제4장 산업 분석

  • 시장 규모·성장 예측
  • 기술 비용 : 유형별
  • 주요 거래
  • 타임라인
  • 사례 연구

제5장 밸류체인

  • 3D 바이오프린팅
    • 하드웨어
    • 재료
  • 의약품 3D 프린팅

제6장 기업

  • 3D 바이오프린팅 기업
  • 3D 프린팅 기업

제7장 용어

제8장 부록

KSA 20.06.17

List of Tables

  • Table 1: Healthcare Trends
  • Table 2: Technology Trends
  • Table 3: Macroeconomic Trends
  • Table 4: Regulatory Trends
  • Table 5: M&As in the 3D Printing Industry
  • Table 6: Funding Activity in the 3D Printing Industry
  • Table 7: Partnerships in the 3D Printing Industry
  • Table 8: Examples of Top 3D Bioprinters
  • Table 9: 3D Bioprinting Companies
  • Table 10: 3D Printing Companies
  • Table 11: Glossary

List of Figures

  • Figure 1: Leaders and Challengers in 3D Printing in Healthcare
  • Figure 2: Pharma Executives Do Not Expect 3D Printing to Have a High Impact on the Industry in 2020
  • Figure 3: Pharma Technology Leaders Level of Understanding of 3D Printing Is Low
  • Figure 4: Pharma Technology Leaders View 3D Printing as an Important Future Technology
  • Figure 5: Pharma Technology Leaders Expect 3D Printing to Have a Positive Impact on the Industry
  • Figure 6: Business Readiness for the Impact of 3D Printing on the Medical Device Industry
  • Figure 7: Current and Future Business Usage of 3D Printing in the Medical Device Industry
  • Figure 8: Change in Business Spend on 3D Printing Over Time in the Medical Device Industry
  • Figure 9: Barriers to Adoption of 3D Printing in the Medical Device Industry
  • Figure 10: Business Action to Develop 3D Printing Expertise in the Medical Device Industry
  • Figure 11: Expected Impact of 3D Printing on Business Objectives Across the Medical Device Industry
  • Figure 12: Online 3D Printing Demand by Industry, 2018
  • Figure 13: Global 3D Printing Revenue to 2030 by Category
  • Figure 14: 3D Bioprinting is One of the Most Expensive 3D Printing Technologies
  • Figure 15: Timeline of 3D Printing in Healthcare
  • Figure 16: 3D Human Tissue Development Using Organovo's NovoGen 3D Bioprinter Platform
  • Figure 17: Biogelx Hydrogels Can Be Tailored to Match the Mechanical Properties of Specific Tissues
  • Figure 18: Cyfuse Biomedical's Proprietary Kenzan Method for 3D Bioprinting of Tissue
  • Figure 19: Cells Growing on Prellis Biologics' Organoid Basket Vascular Tissue Blank
  • Figure 20: Segmental Vitiligo on Left Eyebrow Before and Seven Months After Pigment Cell Transplant
  • Figure 21: 3D Bioprinting of Aspect Biosystem's Airway Smooth Muscle Tissue
  • Figure 22: Poietis' 4G Bioprinting NGB Platform
  • Figure 23: Aprecia Pharmaceutical's ZipDose Technology
  • Figure 24: FabRx's M3DIMAKER 3D Printer and Multiple Combination Pills
  • Figure 25: Case Examples of 3D Systems' VSP Orthopedics Offering
  • Figure 26: Axial3D's Aneurysm Model Used to Practice Procedure and Pre-select Equipment Before Surgery
  • Figure 27: The 3D Printing Industry Value Chain
  • Figure 28: 3D Bioprinting Process
  • Figure 29: 3D Bioprinting Hardware - Leaders and Challengers
  • Figure 30: 3D Bioprinting Materials - Leaders and Challengers
  • Figure 31: 3D Printing of Pharmaceuticals - Leaders and Challengers

Three-dimensional (3D) printing is the process of joining materials to make objects from 3D model data, typically created by building one layer upon the previous layer. This contrasts with subtractive manufacturing, in which parts of a block of material are selectively removed. 3D printing is used across a range of sectors, including industry, electrical, aerospace, automotive, consumer, and healthcare.

In healthcare, 3D bioprinting is used to create living human cells or tissue for use in regenerative medicine and tissue engineering. 3D printing is also used to manufacture precision and personalized pharmaceuticals. Additionally, 3D printing technology is widely used in the manufacturing of medical devices, such as prosthetic limbs, orthopedic and dental implants, surgical instruments, and medical education models. The main focus of this report is 3D bioprinting and the manufacturing of 3D printed pharmaceuticals.

3D bioprinting of human tissue and cells has the potential to solve many critical unmet needs in healthcare, including regenerative medicine, functional organ replacement, and drug discovery. The growing aging population has driven the demand for donor organs, while regenerative medicine using bioprinted, patient-derived stem cells allows for personalized treatment of certain diseases. Use of bioprinted human tissue in drug discovery allows for quicker and more efficient processes, with better outcomes compared to using animal tissue. It also removes the need for animal testing, both in drug and cosmetic development. 3D printing of personalized drugs has the potential to revolutionize the pharmaceutical market. These drugs can be adapted to specific patient requirements, such as age, weight, and comorbidities. This ability to print therapies on demand not only has the potential to make medicine personal to patients, but would equally save millions in costs, resources, and, waste.

Recently, the rapid proliferation of COVID-19 has put an enormous strain on global healthcare systems, with demand for critical medical equipment and supplies mounting. The 3D printing community, from major manufacturers to start-ups and individuals, has responded to the COVID-19 crisis by pledging to support the production of vital medical equipment such as ventilators and personal protective equipment (PPE) for hospitals tackling the pandemic.

Scope

Components of the report include -

  • Key Industry Players - the leading companies in the 3D printing space in healthcare and where they sit in the value chain.
  • Industry Trends - key trends impacting the 3D Printing industry classified into healthcare, technology, macroeconomic, and regulatory themes.
  • Industry Analysis - market value of the entire 3D printing industry to 2025 and 2030, as well as key M&A, funding and partnerships in healthcare. There are also a number of case studies highlighting the different applications of 3D printing in healthcare, including how the 3D printing industry has rallied to provide medical equipment and supplies to healthcare systems fighting the current COVID-19 crisis.
  • Value Chain - Detailed overview of 3D bioprinting and 3D printing of pharmaceuticals by hardware and materials, including leading companies and challengers

Reasons to Buy

  • Develop business strategies by understanding how 3D printing is being used in the healthcare industry today and how the technology is expected to affect the healthcare sector in the future.
  • Stay up to date on the industry's big players in 3D printing and where they sit in the value chain.
  • Identify emerging industry trends to gain a competitive advantage.

Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Industry Players

3 Industry Trends

  • 3.1 Healthcare Trends
  • 3.2 Technology Trends
  • 3.3 Macroeconomic Trends
  • 3.4 Regulatory Trends
  • 3.5 Expected Impact of 3D Printing on the Healthcare Industry
    • 3.5.1 Impact on the Biopharmaceutical Industry
    • 3.5.2 Impact on the Medical Device Industry

4 Industry Analysis

  • 4.1 Market Size and Growth Forecasts
  • 4.2 Cost of Different Types of 3D Printing Technology
  • 4.3 Deals in 3D Printing in Healthcare
  • 4.4 Timeline of 3D Printing in Healthcare
  • 4.5 3D Printing in Healthcare Case Studies
    • 4.5.1 Use of 3D Printing in the Fight Against COVID-19
    • 4.5.2 3D Bioprinting and Regenerative Medicine
    • 4.5.3 Use of 3D Printing in Precision and Personalized Medicines
    • 4.5.4 Use of 3D Printing for Medical Education and Training

5 Value Chain

  • 5.1 3D Bioprinting
    • 5.1.1 3D Bioprinting Hardware
    • 5.1.2 3D Bioprinting Materials
  • 5.2 3D Printing of Pharmaceuticals

6 Companies

  • 6.1 3D Bioprinting Companies
  • 6.2 3D Printing Companies

7 Glossary

8 Appendix

  • 8.1 Bibliography
  • 8.2 Traditional Thematic Research Does a Poor Job of Picking Winners and Losers
  • 8.3 Introducing GlobalData's Thematic Engine
  • 8.4 This Is How It Works
  • 8.5 How Our Research Reports Fit into Our Overall Research Methodology
  • 8.6 About GlobalData
  • 8.7 About the Authors
    • 8.7.1 Healthcare Analyst
    • 8.7.2 Director of Thematic Analysis
    • 8.7.3 Senior Director of Market Research
    • 8.7.4 Global Head and EVP of Healthcare Operations and Strategy
  • 8.8 Contact Us
  • 8.9 Disclaimer
Back to Top
전화 문의
F A Q